We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+7.83%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$658M
AUM Growth
-$44.8M
(-6.4%)
Cap. Flow
-$69.2M
Cap. Flow
% of AUM
-10.5%
Top 10 Holdings %
Top 10 Hldgs %
35.22%
Holding
143
New
39
Increased
27
Reduced
22
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Smith & Nephew
SNN
|
+$10.3M |
| 2 |
STAAR Surgical
STAA
|
+$7.04M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$6.66M |
| 4 |
Zimmer Biomet
ZBH
|
+$6.03M |
| 5 |
Avantor
AVTR
|
+$4.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$10.4M |
| 2 |
Axogen
AXGN
|
+$6.9M |
| 3 |
CELG
Celgene Corp
CELG
|
+$4.72M |
| 4 |
Axsome Therapeutics
AXSM
|
+$4.13M |
| 5 |
Globus Medical
GMED
|
+$3.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.69% |
| 2 | Industrials | 1.24% |
| 3 | Consumer Staples | 0.68% |
| 4 | Materials | 0.13% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABMD
26
PUT
DELISTED
Abiomed Inc
ABMD
| $7.82M | 1.19% |
+30,000
| New | +$7.96M |
|
|
VRAY
27
DELISTED
ViewRay, Inc.
VRAY
| $7.49M | 1.14% |
850,000
-346,805
| -29% | -$2.82M |
|
|
NSTG
28
CALL
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.44M | 1.13% |
245,000
-30,000
| -11% | -$794K |
|
29
PUT
UnitedHealth
UNH
$371B
| $7.32M | 1.11% |
30,000
-30,000
| -50% | -$7.22M |
|
30
Danaher
DHR
$147B
| $7.15M | 1.09% |
56,400
+5,640
| +11% | +$668K |
|
|
XENT
31
DELISTED
Intersect ENT, Inc
XENT
| $7.07M | 1.07% |
310,826
+115,000
| +59% | +$3.1M |
|
|
ARQL
32
DELISTED
Arqule Inc
ARQL
| $6.98M | 1.06% |
633,789
+250,289
| +65% | +$1.74M |
|
33
Gilead Sciences
GILD
$165B
| $6.76M | 1.03% |
100,000
| – | – |
|
|
34
CALL
Smith & Nephew
SNN
$12.6B
| $6.53M | 0.99% |
150,000
-50,000
| -25% | -$2.07M |
|
|
35
Regeneron Pharmaceuticals
REGN
$83.2B
| $6.26M | 0.95% |
+20,000
| New | +$6.66M |
|
36
CALL
Inspire Medical Systems
INSP
$1.73B
| $6.07M | 0.92% |
+100,000
| New | +$5.39M |
|
|
37
CALL
STAAR Surgical
STAA
$1.25B
| $6.06M | 0.92% |
206,200
+150,000
| +267% | +$4.33M |
|
38
Guardant Health
GH
$22.4B
| $6.04M | 0.92% |
70,000
-43,800
| -38% | -$3.35M |
|
39
PUT
Merit Medical Systems
MMSI
$5.36B
| $5.96M | 0.9% |
+100,000
| New | +$5.73M |
|
40
PUT
VanEck Pharmaceutical ETF
PPH
$1B
| $5.87M | 0.89% |
+100,000
| New | +$5.79M |
|
41
AbbVie
ABBV
$438B
| $5.82M | 0.88% |
79,980
+35,000
| +78% | +$2.75M |
|
42
OrthoPediatrics
KIDS
$608M
| $5.63M | 0.86% |
144,408
+24,408
| +20% | +$984K |
|
|
MASI
43
DELISTED
Masimo
MASI
| $5.58M | 0.85% |
37,500
+5,000
| +15% | +$686K |
|
44
CALL
Myriad Genetics
MYGN
$311M
| $5.56M | 0.84% |
+200,000
| New | +$5.65M |
|
45
Bruker
BRKR
$8.58B
| $5M | 0.76% |
+100,000
| New | +$4.21M |
|
46
Orthofix Medical
OFIX
$418M
| $4.96M | 0.75% |
93,794
-11,206
| -11% | -$596K |
|
47
CALL
Glaukos
GKOS
$10.7B
| $4.9M | 0.74% |
+65,000
| New | +$4.66M |
|
|
IVC
48
DELISTED
Invacare Corporation
IVC
| $4.83M | 0.73% |
929,576
+143,137
| +18% | +$933K |
|
|
49
Avantor
AVTR
$9.29B
| $4.77M | 0.72% |
+250,000
| New | +$4.45M |
|
|
AMRN
50
Amarin Corp
AMRN
$298M
| $4.56M | 0.69% |
11,760
| – | – |
|
Similar funds
BCA
RC
DOFI
SR
SCI
LPC
GBCP
SCTC
Pura Vida Investments's Q2 2019 Portfolio in Review
As of Q2 2019, Pura Vida Investments held 143 positions worth $658M, down 6.4% from $703M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Pura Vida Investments withdrew a net $69.2M in Q2 2019, closing 45 positions and reducing 22 holdings. Its most notable exit was Dentsply Sirona, an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 36% a quarter earlier, followed by Industrials and Consumer Staples.
Against the trend, Pura Vida Investments opened a new position in Smith & Nephew worth $10.9M.
- Pura Vida Investments's largest Q2 2019 buy was Smith & Nephew: 250,000 shares worth $10.9M.
- Pura Vida Investments added most to STAAR Surgical in Q2 2019, an estimated $7.04M increase.
- Pura Vida Investments's biggest Q2 2019 reduction was Axsome Therapeutics, cutting an estimated $4.13M.
- Pura Vida Investments fully exited Dentsply Sirona in Q2 2019, selling an estimated $10.4M.
- Pura Vida Investments's ten largest holdings make up 35% of its $658M portfolio in Q2 2019.
- Pura Vida Investments opened 39 new positions and closed 45 in Q2 2019.
- Pura Vida Investments's portfolio value fell 6.4% quarter-over-quarter to $658M.
Based on Pura Vida Investments's 13F filing for Q2 2019, filed 14 Aug 2019.